A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

April 30, 2014

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Human Placenta-Derived Cells PDA001 Intravenous Infusion

DRUG

Vehice Control

Trial Locations (13)

10029

Mt Sinai Hospital, New York

14621

Rochester General Hospital, Rochester

23249

McGuire VA Medical Center, Richmond

32610

University of Florida, Gainesville

37212

Vanderbilt University, Nashville

60637

University of Chicago Medical Center, Chicago

77030

Baylor College of Medicine, Houston

90048

Cedars Sinai Medical Center, Los Angeles

92868

University of California, Irvine, Orange

06510

Yale School of Medicine Digestive Diseases, New Haven

46202-5149

Indiana University, Indianapolis

11794-8173

Stony Brook University, Stony Brook

44106-5066

Case Western Reserve University, Cleveland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Celularity Incorporated

INDUSTRY